ArticleMolecular therapy. Oncology2026
Potency-enhancing mutations in E3-19K and i-leader increase the cytolytic activity of the PH20/
Aleksei A Stepanenko, Anastasiia O Sosnovtseva, Anastasiia A Vasiukova, Marat P Valikhov, Anastasia A Chernysheva, Gaukhar M Yusubalieva, Vladimir P Chekhonin
Abstract read
In one paragraphArticle in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Aleksei A StepanenkoDepartment of Fundamental and Applied Neurobiology, V.P. Serbsky National Medical Research Center of Psychiatry and Narcology of the Ministry of Health of the Russian Federation, 119034 Moscow, Russia.
Anastasiia O SosnovtsevaDepartment of Fundamental and Applied Neurobiology, V.P. Serbsky National Medical Research Center of Psychiatry and Narcology of the Ministry of Health of the Russian Federation, 119034 Moscow, Russia.
Anastasiia A VasiukovaDepartment of Fundamental and Applied Neurobiology, V.P. Serbsky National Medical Research Center of Psychiatry and Narcology of the Ministry of Health of the Russian Federation, 119034 Moscow, Russia.
Marat P ValikhovDepartment of Fundamental and Applied Neurobiology, V.P. Serbsky National Medical Research Center of Psychiatry and Narcology of the Ministry of Health of the Russian Federation, 119034 Moscow, Russia.
Anastasia A ChernyshevaDepartment of Fundamental and Applied Neurobiology, V.P. Serbsky National Medical Research Center of Psychiatry and Narcology of the Ministry of Health of the Russian Federation, 119034 Moscow, Russia.
Gaukhar M YusubalievaLaboratory of Cell Technologies, Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency of the Russian Federation, 115682 Moscow, Russia.
Vladimir P ChekhoninDepartment of Fundamental and Applied Neurobiology, V.P. Serbsky National Medical Research Center of Psychiatry and Narcology of the Ministry of Health of the Russian Federation, 119034 Moscow, Russia.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
The oncolytic adenovirus Ad5-delta-24-RGD (Ad5Δ24RGD) exhibits suboptimal therapeutic efficacy in high-grade glioma. Here, we show that combining two specific potency-enhancing mutations in
Indexed as
adenovirus death proteinE3-19Kglioblastomahyaluronidase PH20i-leaderL3-23KL5-fiberMT: Regular Issuenelfinavironcolytic adenovirusverapamil
Identifiers
PMID41716467
PMCPMC12914292
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390